Deutsche Bank lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $29 from $35 and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Growth Potential Despite Setbacks with Promising Pipeline and Core Business Expansion
- Video: Soleno Therapeutics stock rallies on competitor’s failed trial
- Micron reports Q4 beat, Instagram reports 3B MAUs: Morning Buzz
- Acadia Pharmaceuticals PWS miss ‘disappointing but expected,’ says Leerink
- Soleno shares jump following competitor Acadia’s trial miss